Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

doi:10.1111/bjh.12354

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

British journal of haematology - 1 Jul 2013

Mallo Mar, Del Rey Mónica, Ibáñez Mariam, Calasanz M José, Arenillas Leonor, Larráyoz M José, Pedro Carmen, Jerez Andrés, Maciejewski Jaroslaw, Costa Dolors, Nomdedeu Meritxell, Diez-Campelo María, Lumbreras Eva, González-Martínez Teresa, Marugán Isabel, Such Esperanza, Cervera José, Cigudosa Juan C, Alvarez Sara, Florensa Lourdes, Hernández Jesús M, Solé Francesc

Abstract excerpt

Lenalidomide is an effective drug in low-risk myelodysplastic syndromes (MDS) with isolated del(5q), although not all patients respond. Studies have suggested a role for TP53 mutations and karyotype complexity in disease progression and outcome. In order to assess the impact of complex karyotypes on treatment response and disease progression in 52 lenalidomide-treated patients with del(5q) MDS, conventional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosome Banding

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chromosome Deletion

Share to Chromosomes, Human, Pair 5

Share to Immunologic Factors

Share to In Situ Hybridization, Fluorescence

Share to Lenalidomide

Share to Myelodysplastic Syndromes

Share to Thalidomide

Source

Open in PubMed

Identifiers

PMID: 23614682
DOI: 10.1111/bjh.12354

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.PMID 23614682Read ↗

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.Semantic proximity Read ↗

Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).Semantic proximity Read ↗

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.Semantic proximity Read ↗

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.Semantic proximity Read ↗

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.Semantic proximity Read ↗

Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).Semantic proximity Read ↗

Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroupSemantic proximity Read ↗

Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.Semantic proximity Read ↗

Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.Semantic proximity Read ↗

Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.Semantic proximity Read ↗

Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II studySemantic proximity Read ↗

Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.